Episode summary
Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US | Bloomberg Intelligence
Bloomberg Intelligence
· · 23 min · Hosts: Paul Sweeney, Scarlet Fu · Guests: Michael Shah, Liana Baker, Mary Ross Gilbert, Michael Halen
Summary
Novo Nordisk is cutting cash-pay prices on Wegovy and Ozempic in the US, with introductory doses around $199 a month and later doses about $349, directly undercutting Eli Lilly’s obesity-drug pricing. The Bloomberg Intelligence analyst said the move is aimed at new patient starts in a highly price-sensitive market, where US penetration remains in the low single digits and could expand as prices fall and more coverage opens through Medicare and Medicaid changes.
The discussion also covered compounding copycat GLP-1 drugs, which the analyst said remain a meaningful channel with about 1.2 million patients, but would face pressure as branded products become cheaper. On the broader pharma landscape, the analyst argued that obesity remains an attractive area because it is large, underpenetrated, and useful for offsetting later patent expirations, which helps explain the ongoing wave of pharma M&A.
The episode then shifted to Clayton Dubilier & Rice’s agreement to buy Sealed Air for $6.2 billion, and to retail, where Gap, Aritzia, off-price chains, Dillard’s and Ralph Lauren were cited as relatively strong names heading into 2026. Restaurant commentary was more mixed: fine dining improved, quick service recovered after fixing value offers, and beef inflation remains a margin headwind for burger and steak chains.
Key takeaways
- Novo is using lower cash-pay prices to compete for new obesity-drug users, and the analyst said it is undercutting Lilly by about $100 per dose.
- The analyst said US GLP-1 penetration remains in the low single digits, with Medicare and Medicaid changes potentially opening access to millions more patients.
- Cheaper branded GLP-1s should narrow the appeal of compounded copycat drugs, which the analyst estimated at about 1.2 million patients.
- Obesity is drawing pharma M&A because it is large, underpenetrated and can help offset patent expirations later in the decade.
- Retail winners cited by the analyst included Gap, Aritzia, Dillard’s and Ralph Lauren, while Kohl’s and Abercrombie’s namesake brand were weaker spots.
- Restaurant chains improved as value offers returned, but beef inflation is still pressuring burger and steak concepts in the fourth quarter.
Notable quotes
“starting doses being reduced to $200 per month and then doses thereafter um being charged at an average of $350 per month compared to $500 previously”
“this is basically um a ploy to basically compete for new patient starts”
“we think that it can unlock, you know, 7 to 8 million um, patients”
“I believe that, you know, 1.2 million patients are on compounding GLP1 at the moment”
“the share price is sort of below where it's trading on the margin. So not a huge premium here. In fact no premium”
How the episode opens
Bloomberg Audio Studios podcasts radio news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m.
Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. Listen on demand wherever you get your podcasts or watch us live on YouTube. I feel like we have to talk about what's going on in biotech.
It's M&A Monday, Paul. And there's been this trend, of course, of the big pharma companies desperate to refill their pipeline. It's getting competitive now, and they're going competing on price.
That's what I'm kind of noticing here. It went from be like a rare to find it, now it's everywhere, and now they're competing on on price. So, it's a good thing if you are looking to get in on the anti-obesity drugs and you're looking for uh a more affordable price because uh the companies are doing what they can to appeal to consumers.
Michael Shaw is Bloomberg Intelligence senior farmer senior pharma biotech analyst uh joining us now. And Michael um Nova Nordisk is now undercutting Eli Lilly's obesity drug price. Tell us exactly what they're doing here because my understanding is that both these companies recently worked out a deal with the White House to reduce prices overall.
Yeah, thanks. Um so absolutely this is I mean this is obviously ahead of the White House deal. So, you're seeing starting doses being reduced to $200 per month and then doses thereafter um being charged at an average of $350 per month compared to $500 previously.
Um so, I mean, you know, those prices kind of align to, you know, the pricing in the in the White House statement um coming from Trump RX. Um but compared to Lily, um I mean, they're undercutting them by about, you know, $100, um at each dose.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- obesity drug pricing
- private equity m&a
- retail sales outlook
- restaurant sales outlook
- tariff impacts on margins
Companies and tickers mentioned
- NVO
- LLY
- RL
- M
- BURL
- URBN
- MCD
- DPZ
- Novo Nordisk
- Eli Lilly & Co.
- Sealed Air Corp.
- Clayton Dubilier & Rice
- Ralph Lauren
- Gap
- Macy's
- Dillard's
- Burlington
- Urban Outfitters
- McDonald's
- Domino's
- Aritzia
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Anthropic’s IPO Is Said to Be About Six Times Oversubscribed | Bloomberg Intelligence -
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
